WallStreetZenWallStreetZen

NASDAQ: AURA
Aura Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AURA

Based on 2 analysts offering 12 month price targets for Aura Biosciences Inc

Min Forecast
$19.00+225.9%
Avg Forecast
$22.00+277.36%
Max Forecast
$25.00+328.82%

Should I buy or sell AURA stock?

Based on 2 analysts offering ratings for Aura Biosciences Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AURA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates AURA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their AURA stock forecasts and price targets.

AURA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-26
lockedlocked$00.00+00.00%2025-03-25

1 of 1

Forecast return on equity

Is AURA forecast to generate an efficient return?

Company
-54.2%
Industry
80.47%
Market
61.57%
AURA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AURA forecast to generate an efficient return on assets?

Company
-45.13%
Industry
23.3%
AURA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AURA earnings per share forecast

What is AURA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.14
Avg 2 year Forecast
-$2.23
Avg 3 year Forecast
-$1.64

AURA revenue forecast

What is AURA's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$33.5M

AURA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AURA$5.83$22.00+277.36%Buy
ATXS$5.16$29.00+462.02%Buy
ATAI$1.50$10.50+600.00%Strong Buy
TERN$3.30$15.83+379.79%Buy
XOMA$24.04$69.50+189.10%Strong Buy
View Top Biotech Stocks

Aura Biosciences Stock Forecast FAQ

Is Aura Biosciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AURA) stock is to Buy AURA stock.

Out of 2 analysts, 0 (0%) are recommending AURA as a Strong Buy, 2 (100%) are recommending AURA as a Buy, 0 (0%) are recommending AURA as a Hold, 0 (0%) are recommending AURA as a Sell, and 0 (0%) are recommending AURA as a Strong Sell.

If you're new to stock investing, here's how to buy Aura Biosciences stock.

What is AURA's earnings growth forecast for 2025-2027?

(NASDAQ: AURA) Aura Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.32%.

Aura Biosciences's earnings in 2025 is -$86,919,000.On average, 4 Wall Street analysts forecast AURA's earnings for 2025 to be -$107,231,041, with the lowest AURA earnings forecast at -$126,567,786, and the highest AURA earnings forecast at -$90,405,562. On average, 3 Wall Street analysts forecast AURA's earnings for 2026 to be -$111,836,702, with the lowest AURA earnings forecast at -$136,612,849, and the highest AURA earnings forecast at -$92,916,827.

In 2027, AURA is forecast to generate -$82,369,512 in earnings, with the lowest earnings forecast at -$82,369,512 and the highest earnings forecast at -$82,369,512.

What is AURA's revenue growth forecast for 2027-2027?

(NASDAQ: AURA) Aura Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 149.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.43%.

Aura Biosciences's revenue in 2025 is $0.

In 2027, AURA is forecast to generate $1,682,547,952 in revenue, with the lowest revenue forecast at $1,682,547,952 and the highest revenue forecast at $1,682,547,952.

What is AURA's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: AURA) forecast ROA is -45.13%, which is lower than the forecast US Biotechnology industry average of 23.3%.

What is AURA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AURA price target, the average AURA price target is $22.00, with the highest AURA stock price forecast at $25.00 and the lowest AURA stock price forecast at $19.00.

On average, Wall Street analysts predict that Aura Biosciences's share price could reach $22.00 by Mar 26, 2026. The average Aura Biosciences stock price prediction forecasts a potential upside of 277.36% from the current AURA share price of $5.83.

What is AURA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AURA) Aura Biosciences's current Earnings Per Share (EPS) is -$1.75. On average, analysts forecast that AURA's EPS will be -$2.14 for 2025, with the lowest EPS forecast at -$2.52, and the highest EPS forecast at -$1.80. On average, analysts forecast that AURA's EPS will be -$2.23 for 2026, with the lowest EPS forecast at -$2.72, and the highest EPS forecast at -$1.85. In 2027, AURA's EPS is forecast to hit -$1.64 (min: -$1.64, max: -$1.64).

What is AURA's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: AURA) forecast ROE is -54.2%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.